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Abstract Double-stranded (ds) RNA is a biologically active
component of many viruses including rhinoviruses infecting the
upper respiratory tract. Mucus production is a common symp-
tom of such infections. Here, we show that mucin, the glyco-
protein subunit of mucus gels, is transcriptionally upregulated in
an NF-UB- and p38-dependent manner when homogeneous cul-
tures of epithelial cells are exposed to dsRNA. Furthermore,
upstream of p38 in this system, dsRNA stimulates the extracel-
lular release of ATP and activation of cell surface ATP recep-
tors, which are G protein-coupled. This results in the stimulation
of phospholipase C and protein kinase C. These ¢ndings suggest
that ATP receptor antagonists could be used to modulate mucus
production induced by virus.
, 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Over the course of evolution, mammalian hosts have ac-
quired diverse mechanisms to limit viral infection. For exam-
ple, binding of viral double-stranded (ds) RNA to protein
kinase R (PKR) and oligoadenylate synthase stimulates these
enzymes to block protein synthesis via e¡ects on elongation
initiation factor 2K [1] and RNase L [2]. The ultimate conse-
quence of these e¡ects is to induce apoptosis of the host cell
[3], which limits spread of the virus.
Infection can also be limited by the production of antiviral
cytokines. Among these are interferons, which impair viral
gene expression [4,5], as well as interleukin (IL)-6 [6] and
IL-12 [7], which contribute to the activation of cytotoxic
T cells. Recent evidence demonstrates a role for Toll-like re-
ceptor 3 in the induction of interferon-L [8].
Here we report details of yet another mechanism used to
limit infection, namely the production of a physical mucus
barrier. Mucus overproduction has long been recognized as
a symptom of respiratory viral infections, but its etiology is
poorly understood. The present results are the ¢rst to show
that mucin is induced as a direct e¡ect of viral dsRNA on
epithelial cells. As revealed below, the signaling pathways me-
diating mucin induction by dsRNA resemble those shown
previously to mediate cytokine induction. These pathways in-
clude the activation of mitogen-activated protein kinases
(MAPK) [9,10] and nuclear factor UB (NF-UB) [11^13].
In this report, we speci¢cally show that the mucin gene
MUC2 is transcriptionally upregulated by dsRNA and that,
just as in the case of IL-6, MUC2 induction is an NF-UB-
dependent and PKR-independent process that requires activa-
tion of the MAPK, p38 [3]. Furthermore, we show that signal-
ing upstream of p38 requires the autocrine activation of ATP
receptors. This mechanism had been previously implicated in
the epithelial response to bacterial £agellin [14] and may also
represent a general mechanism for transmitting dsRNA-initi-
ated signals to MAPK and NF-UB.
2. Materials and methods
2.1. Reagents
dsRNA and single-stranded (ss) RNA were from Amersham Phar-
macia Biotech and histone was from Gibco BRL. Chemical inhibitors
ca¡eic acid phenethyl ester (CAPE), bisindolylmaleimide I, G06983,
U73122, U73433, D609, suramin, and glibenclamide were from
Calbiochem (La Jolla, CA, USA). 2-Aminopurine (2-AP), reactive
blue 2 (RB2), pyridoxal-phosphate-6-azophenyl-2P,4P-disulfonic acid
(PPADS), and gadolinium III chloride (GD3) were purchased from
Sigma (St. Louis, MO, USA). SB202190 was purchased from A.G.
Scienti¢c (San Diego, CA, USA), and ATP was purchased from In-
vitrogen (Carlsbad, CA, USA).
2.2. Viral homologues
Both dsRNA and ssRNA were diluted to a concentration of 2 mg/
ml in sterile H2O and then stored at 320‡C until diluted in serum-free
medium (SFM) for use at 400 ng/ml. Histone was stored as 1 mg/ml
and used at 1 Wg histone/Wg RNA.
2.3. Cell culture
Two epithelial cell lines were used in these studies. HM3 cells (from
colon) were maintained in Dulbecco’s modi¢ed Eagle’s medium.
NCIH292 cells (from airway) were maintained in RPMI 1640 me-
dium. All media contained 10% fetal bovine serum, 100 U/ml peni-
cillin, and 0.1 mg/ml streptomycin.
2.4. Cloning and sequencing of the 5P-£anking region of MUC2,
plasmid construction, transfection, and luciferase assay
The 5P-£anking region of the human mucin gene MUC2 was cloned
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and stably transfected into HM3 cells and used as described [14].
Stable transfectants are called HM3-MUC2 cells. Histone plus either
dsRNA or ssRNA in SFM was incubated with the cells for speci¢ed
times and the cells were then harvested for luciferase assay. Chemical
inhibitors were preincubated with cells for 30^60 min.
2.5. Reverse transcription polymerase chain reaction (RT-PCR)
RNA was isolated from cells using Trizol (Gibco BRL) and 5 Wg
was used for reverse transcription using Superscript reverse transcrip-
tase (Gibco BRL). One tenth of the reaction product was used as a
template for PCR ampli¢cation with Taq polymerase (AmpliTaq,
Roche). Custom primers for MUC2 gene were: forward 5P-CA-
GAGGGCAGAACCCGATACC-3P, reverse 5P-ACATCGGGCTG-
GTTGATCTTC-3P. GAPDH primers and 18S primers were used as
controls.
2.6. RNase protection assay (RPA)
The MUC2 probe for RPA was constructed using PCR with prim-
ers corresponding to nucleotides 423^639 of the cDNA sequence as
previously described [15]. The resulting 216 bp cDNA was TA-cloned
into pCRII vector (Invitrogen). The vector was linearized with BamHI
in a 100 Wl volume at 37‡C overnight. The DNA was treated with
proteinase K before extracting with equal volumes of phenol/chloro-
form/isoamyl alcohol. The extract was precipitated with ammonium
acetate and ethanol for 15 min at 380‡C and redissolved in diethyl-
pyrocarbonate-treated water. Riboprobe was synthesized in the pres-
ence of 32P-labelled UTP using linearized and puri¢ed DNA template.
It was then subjected to RNase-free DNase I at 37‡C, phenol ex-
tracted and ethanol precipitated. The pellet was resuspended in gel
loading bu¡er. The probe was puri¢ed on a polyacrylamide gel run at
300 V for 1 h. The target band on the gel was visualized by exposure
to X-omat AR ¢lm (Kodak). The band was excised and incubated in
elution bu¡er (RPA II kit, Ambion). The puri¢ed probe was diluted
in 1Uhybridization bu¡er so that each sample had 500 000 cpm. After
10 Wl of probe was added, the samples were heated at 95‡C for 5 min
before hybridizing at 45‡C overnight. After hybridization, 200 Wl of
diluted RNase A and T (RPAII kit, Ambion) were added to each
sample and they were incubated at 37‡C for 30 min. The samples
were precipitated and redissolved in 4 Wl of gel loading bu¡er, dena-
tured at 95‡C for 5 min before running on a 0.5 mm thick 6% poly-
acrylamide/8 M urea gel at 1500 V for 2 h. The gel was dried and
exposed to X-omat AR ¢lm at 380‡C for 2^7 days.
2.7. Terminal deoxynucleotidyl transferase-mediated dUTP nick end
labelling (TUNEL) assay
NCIH292 cells were grown to 50^60% con£uence in four chamber
slides (LabTek II, Nalge Nunc International) and were pretreated
with or without 2-AP for 1 h prior to addition of dsRNA (400 ng/
ml). After 24 h of incubation with dsRNA, an apoptosis assay kit
(ApopTag, Intergen) using indirect £uorescent staining of cells was
used to detect fragmentation of nuclei undergoing apoptosis. The
¢xed slides were then viewed under a £uorescence microscope (Nikon
Eclipse E600). The image was captured using a Zeiss Axiocam digital
camera and software.
2.8. Immunoblots and kinase assays
Protein was isolated from cells and probed with speci¢c antibodies
for detection of phosphorylated residues. Cell lysates were pre-cleared
by centrifugation at 10 000 rpm for 10 min at 4‡C and total protein
concentrations were determined using the Bradford protein assay
(Bio-Rad). Equal amounts of lysate were run directly with the indi-
cated antibodies. Lysates were incubated with anti-p38 MAPK anti-
body (New England Biolabs) and protein A agarose beads (Santa
Cruz Biotechnology) overnight at 4‡C. The lysate^antibody^bead
complex was spun down and washed three times with lysis bu¡er
(20 mM Tris^HCl, 150 mM NaCl, 0.5% Triton X-100, 0.1% sodium
dodecyl sulfate (SDS), 1 mM EDTA, 1 mM sodium orthovanadate).
Following the ¢nal wash, 40 Wl of SDS gel loading bu¡er was added,
the mixture was heated at 100‡C for 3 min, and proteins were resolved
by SDS^polyacrylamide gel electrophoresis (PAGE). For immunoblot
analysis, proteins were transferred to nitrocellulose membranes using
the Bio-Rad Mini Trans-Blot Electrophoretic Transfer Cell. Mem-
branes were blocked in phosphate-bu¡ered saline containing 0.1%
Tween (PBS/Tween) and supplemented with 5% bovine serum albu-
min. After 1 h at room temperature, blots were washed with PBS/
Tween and incubated with the appropriate antibody overnight at 4‡C.
After removing primary antibody with several washes of PBS/Tween,
the blot was placed in the appropriate horseradish peroxidase-conju-
gated secondary antibody for 45 min. After several washes, the anti-
body^antigen complexes were visualized using the ECL chemilumines-
cence detection system (Amersham Life Sciences). For detection of
Jun N-terminal kinase (JNK) activity, a stress-activated protein kinase
(SAPK)/JNK assay kit (Cell Signaling Technology) was used to ‘pull
down’ SAPK using c-Jun fusion protein beads prior to performing a
kinase reaction in the presence of ATP. After running the reaction
products on SDS^PAGE, c-Jun phosphorylation was detected using a
phospho-c-Jun antibody.
2.9. ATP assay
Direct measurement of ATP release was performed by growing
NCIH292 cells to con£uence in 12 well culture plates at 37‡C, and
then placing them in SFM overnight. The next day, cells were treated
with ssRNA or dsRNA in a total of 1 ml medium per well. At
indicated times after RNA addition, 100 Wl volumes were carefully
removed from the surface without perturbing the cells and added to
100 Wl luciferin/luciferase reagent (ENLITEN ATP assay system,
Promega) before reading in a Monolight luminometer.
2.10. Statistics and densitometry
All data are expressed as meanRS.E.M. One way analysis of var-
iance was used to determine statistically signi¢cant di¡erences be-
tween groups. A probability of 6 0.05 for the null hypothesis was
accepted as indicating a statistically signi¢cant di¡erence. Densitom-
etry measurements of immunoblot bands were carried out using the
histogram calculator in Adobe Photoshop (Adobe Systems). Blots
Fig. 1. dsRNA stimulates mucin gene (MUC2) transcription.
A: RT-PCR shows induction of endogenous MUC2 by dsRNA (4 h
incubation), HM3 cells. B: MUC2 promoter is stimulated by
dsRNA (4 h incubation) in a dose-dependent manner, as re£ected
by activity of the reporter gene, luciferase, in HM3-MUC2 cells.
C: Time-dependent activity of MUC2 promoter in HM3-MUC2
cells exposed to dsRNA (400 ng/ml). Data points are averages from
three separate experiments, each containing n=3 samples. An aster-
isk signi¢es dsRNA and ssRNA responses are di¡erent (P6 0.05).
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were normalized after reprobing with appropriate antibody to ensure
equal loading.
3. Results
3.1. dsRNA stimulates mucin synthesis in epithelial cells
Mucin production increases in the respiratory tract during
virus infection [16] but whether this is due to direct e¡ects of
virus or is secondary to in£ammation is unknown. Here, we
tested the direct e¡ects of viral dsRNA on mucin synthesis in
two human epithelial cell lines (HM3 and NCIH292). Because
preliminary studies showed that responses to rhinovirus
dsRNA [17] were the same as those to synthetic dsRNA, we
used the synthetic form for convenience. Using ssRNA as a
negative control, we observed increased steady-state levels of
MUC2 RNA in response to dsRNA (Figs. 1A and 2B). These
results support the view that mucin overproduction during
viral infection is at least partly due to a direct e¡ect of dsRNA
on epithelial cells. We illustrate data from HM3 and
NCIH292 cells interchangeably below, as the two cell lines
showed the same pattern of response to inhibitors.
3.2. Mucin upregulation by dsRNA is controlled at the level
of transcription
To determine whether mucin induction by virus, like that
by bacteria [14,18], is controlled at the level of transcription,
we performed experiments using HM3 cells stably transfected
with a luciferase reporter under the control of a 2.8 kb frag-
ment of the MUC2 5P-£anking region [14,18]. In response to
dsRNA, luciferase activity increased in both a dose- and time-
dependent manner (Fig. 1B,C), strongly suggesting that the
steady-state responses shown in Figs. 1A and 2B are mediated
by transcriptional induction involving response elements
present in the 5P-£ank of MUC2.
3.3. Mucin induction by dsRNA is PKR-independent
Antiviral responses, once thought to be principally depen-
dent on the dsRNA-dependent kinase, PKR, have been shown
in some cases to be PKR-independent and to involve other
upstream mediators [9,10]. The compound 2-AP inhibits
dsRNA-initiated, PKR-dependent processes such as transla-
tional inhibition [19] and apoptosis [20]. In our model, despite
2-AP’s ability to block dsRNA-induced apoptosis (Fig. 2A), it
had no e¡ect on mucin induction (Fig. 2B,C). Thus, the in-
duction of mucin by dsRNA does not require PKR.
3.4. Mucin induction by dsRNA is p38- and NF-UB-dependent
In agreement with data previously obtained in ¢broblasts
[3,10], we found that dsRNA stimulates JNK and p38 in ep-
ithelial cells (Fig. 3A). In addition, consistent with [21], we
Fig. 2. PKR inhibitor 2-AP inhibits apoptosis but not MUC2 induc-
tion by dsRNA. A: TUNEL assay shows apoptotic cells following
24 h incubation with dsRNA (left panel), but not when dsRNA ex-
posure is preceded (1 h) and coextensive with exposure to 2-AP
(5 mM; right panel), HM3 cells. B: RPA shows MUC2 RNA in-
duction by dsRNA (4 h incubation). 2-AP treatment (as in A) does
not inhibit the response. Densitometry data in lower panel are con-
trolled for sample loading using a probe for the housekeeping gene,
cyclophilin, HM3 cells. C: MUC2 promoter activity monitored by
luciferase is una¡ected by 2-AP in HM3-MUC2 cells (administered
as in A).
Fig. 3. p38 and NF-UB are required for mucin induction by
dsRNA. A: Densitometry values re£ecting p38 phosphorylation and
JNK activity in response to dsRNA, in the presence and absence of
kinase inhibitor SB202190 (1 h preincubation and 1 h co-exposure
with dsRNA) in NCIH292 cells. In agreement with [21], p38 is in-
hibited at low, and JNK at high, concentrations of this drug. B: Ef-
fect of low and high doses of inhibitor on mucin induction by
dsRNA and TPA. Data are averages of three separate experiments
and were normalized in A by reprobing immunoblots with anti-p38
to control for sample loading. C: MUC2 promoter activity moni-
tored by luciferase is inhibited by the NF-UB inhibitor CAPE (1 or
4 Wg/ml; 1 h pretreatment and 4 h co-treatment with dsRNA) in
HM3-MUC2 cells. An asterisk signi¢es e¡ects of inhibitors were sig-
ni¢cant at the level of P6 0.05.
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found that the inhibitor SB202190 selectively inhibits p38 at
low doses, while it inhibits both p38 and JNK at 80 WM (Fig.
3A). Because mucin induction by dsRNA, but not 12-O-tet-
radecanoylphorbol 13-acetate (TPA) (which acts through
JNK), was inhibited at the lower dose (Fig. 3B), we conclude
that mucin induction by dsRNA requires activation of p38.
As suggested [9], the same upstream dsRNA-sensing mecha-
nisms that stimulate p38 may also stimulate NF-UB. Indeed,
data in Fig. 3C illustrate that mucin induction, already shown
to be sensitive to the p38 inhibitor SB202190, is also sensitive
to CAPE, which inhibits the binding of NF-UB to DNA. A
requirement for NF-UB is consistent with the presence of an
NF-UB site at approximately (3) 1.5 kb in the MUC2 se-
quence driving the luciferase reporter [22]. Taken together,
and in agreement with [23], these data suggest the existence
of a linear pathway in which p38 acts upstream of NF-UB to
stimulate gene expression.
3.5. dsRNA activates mucin via protein kinase C (PKC),
phospholipase C (PLC) and a G protein-coupled receptor
(GPCR)
To de¢ne additional signaling components, we screened a
broad range of compounds for their ability to block mucin
induction by dsRNA. Among the most potent were the PKC
inhibitors bisindolylmaleimide I and GO6983 (Fig. 4A). Sen-
sitivity to these drugs identi¢es PKC, for the ¢rst time, as a
contributor to antiviral signaling. That PKC’s speci¢c role in
dsRNA signaling may be to stimulate p38 is possible based on
results in cardiac myocytes [24].
We next addressed the question of how dsRNA activates
PKC. This enzyme is commonly activated by diacylglycerol, a
product of phosphatidylinositol 4,5-bisphosphate cleavage by
PLC. Supporting the involvement of such a mechanism in
dsRNA signaling, the PLC inhibitors U73122 and D609
strongly attenuated mucin induction (Fig. 4B). Furthermore,
attenuation of the response in the presence of the GPCR-
blocking agent suramin (Fig. 4C) suggested that dsRNA-ini-
tiated signaling includes a GPCR^PLC^PKC signaling cas-
sette.
3.6. Nucleotide receptor signaling is required for the induction
of mucin by dsRNA
Some of the most extensively analyzed GPCRs on the sur-
face of respiratory epithelial cells are members of the P2Y
family of nucleotide receptors responsible for chloride and
macromolecule secretion [25]. We recently reported that
such receptors mediate epithelial cell responses to bacterial
£agellin [14]. A role for P2Y receptors was equally apparent
in this study. Thus, P2Y, but not P2X, receptor antagonists
Fig. 4. PKC, PLC, and GPCR inhibitors inhibit MUC2 induction
by dsRNA. A: E¡ects of PKC inhibitors bisindolylmaleimide (Bis)
and GO6983. B: E¡ects of PLC inhibitors U73122 and D609.
C: E¡ect of the GPCR inhibitor suramin. All administered as 1 h
pretreatment and 4 h co-treatment with dsRNA in HM3-MUC2
cells. An asterisk signi¢es e¡ects of drugs were signi¢cant at the lev-
el of P6 0.05.
Fig. 5. Evidence for involvement of nucleotide receptors in the re-
sponse to dsRNA. A: MUC2 promoter activity monitored by lucif-
erase is inhibited by RB2, an inhibitor of P2Y nucleotide receptors,
but not PPADS, an inhibitor of P2X nucleotide receptors (4 h incu-
bation with dsRNA). B: Same as in A, showing inhibition of
MUC2 promoter activity by ATP conductance-blocking drugs, gli-
benclamide and GD3+. C: Time-dependent luciferin/luciferase assay
comparing ATP release from cells stimulated by ssRNA and
dsRNA. D: Luciferase activity driven by NF-UB response elements
stimulated by dsRNA (4 h incubation) with and without 1 h pre-
treatment with RB2. Mucin and NF-UB induction are shown in the
presence and absence of inhibitors administered as 1 h pretreatment
and 4 h co-treatment with stimulus (dsRNA) in HM3-MUC2 cells.
An asterisk signi¢es e¡ects of drugs were signi¢cant at the level of
P6 0.05.
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(RB2 vs. PPADS) strongly inhibited mucin induction by
dsRNA (Fig. 5A). The involvement of P2Y receptors implies
that extracellular nucleotide is somehow presented to these
receptors during dsRNA exposure. Hypothesizing that
dsRNA might cause ATP to be released extracellularly, we
examined the e¡ect on mucin induction of glibenclamide
and GD3+, two compounds known to inhibit ATP transport
across cell membranes [26,27]. The inhibitory e¡ect of both
compounds (Fig. 5B) supported a role for ATP in the re-
sponse, and implied that ATP is, indeed, released from cells
upon dsRNA exposure. Direct evidence for this was provided
by an assay of ATP in the medium of dsRNA-exposed cells
(Fig. 5C). Importantly, mucin induction by irrelevant stimuli
(e.g. lipopolysaccharide (LPS)) was una¡ected by RB2, gliben-
clamide, and gadolinium (not shown), indicating speci¢city.
3.7. Nucleotide receptors are also required for NF-UB
activation in response to dsRNA
NF-UB is required for the induction of both mucin (Fig.
3C) and cytokines [3,10] and may coordinate other dsRNA-
evoked responses as well. That NF-UB activity was, itself,
reduced by RB2 (Fig. 5D) suggested that nucleotide receptors
might control a wide array of dsRNA- and NF-UB-dependent
responses.
3.8. dsRNA also stimulates p38 and JNK via nucleotide
receptors
JNK has been implicated in the induction of interferon [10],
and p38 has been implicated in the induction of IL-6 [3], by
dsRNA. Further supporting a general role for nucleotide re-
ceptors in dsRNA signaling are data showing that the activa-
tion of these two kinases was strikingly reduced in the pres-
ence of RB2 (Fig. 6A,B).
4. Discussion
Apoptosis and cytokine production are well-documented
responses of host cells to viral dsRNA. The present study
identi¢es mucin induction as a third major defensive response.
Our results show that dsRNA stimulates mucin transcription
in an NF-UB-dependent, p38-dependent, PKR-independent
manner similar to that controlling the induction of IL-6 [3].
The present work also provides new information regarding
mechanisms of signal transduction upstream of p38 in this
system. Speci¢cally, our data indicate that dsRNA causes
ATP to be released extracellularly and that this is followed
by activation of cell surface ATP receptors, which are G pro-
tein-coupled. Like other examples of GPCR activation, this
results in the stimulation of PLC and PKC. Downstream
events relevant to mucin induction include activation of p38
and NF-UB. Our model is shown in Fig. 7.
A conclusion of the present study is that p38, but not JNK,
is required for mucin induction. This is based on use of the
compound SB202190. Earlier work had shown that SB202190
Fig. 6. Evidence for involvement of nucleotide receptors in the acti-
vation of p38 and JNK by dsRNA. A: As shown previously [3],
p38 is phosphorylated by dsRNA. Here p38 phosphorylation is
shown in NCIH292 cells; the response is blocked by nucleotide re-
ceptor antagonist RB2. Band density in anti-phospho-p38 immuno-
blot (upper panel) is normalized with respect to band density in
anti-p38 immunoblot (lower panel) prior to quanti¢cation (histo-
gram). B: As in A, but data here are from a JNK kinase assay in
which JNK was pulled down from equal amounts of protein extract
using c-Jun fusion protein beads and the c-Jun fusion protein was
used as a substrate for kinase activity. c-Jun phosphorylation was
monitored at Ser63 by Western blotting and chemiluminescence. All
data are typical of at least two experiments, each with n=2. Kinase
activities were measured in the presence and absence of RB2 admin-
istered as 1 h pretreatment and 1^2 h co-treatment with dsRNA.
Fig. 7. Model of host in£ammatory response to viral dsRNA in epi-
thelial cells. See explanation in the text.
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inhibits both p38 and JNK at V80 WM, but inhibits p38
exclusively at V10 WM [21]. Data in Fig. 3 con¢rm this.
Moreover, the data clearly show that mucin induction by
dsRNA is inhibited at the lower dose, implicating p38 in the
response.
As mentioned above, it had been shown previously that p38
was required for IL-6 induction by dsRNA [3]. Although that
study also demonstrated activation of two kinases acting im-
mediately upstream of p38 (MKK3 and MKK6), it did not
address mechanisms acting further upstream. Our evidence
that mucin induction is blocked by bisindolylmaleimide and
GO6983 implicates PKC in this pathway. Based on previous
evidence that PKC is capable of activating p38 [28], we pos-
tulate that the role of PKC in this pathway is to stimulate
p38. Furthermore, based on evidence that p38 is required for
activation of NF-UB in the context of Haemophilus infection
[23], we speculate that this interaction may also occur in path-
ways stimulated by dsRNA.
A common mechanism for activating PKC is via PLC. That
this, too, plays a role in dsRNA-induced responses was indi-
cated by results obtained using compounds U73122 and D609
(Fig. 4). PLC involvement had been observed previously in a
model of mucin induction by bacterial £agellin [14]. In that
model, PLC activation was a consequence of autocrine/para-
crine stimulation of P2Y nucleotide receptors. The present
results show that this also occurs in the context of dsRNA:
thus, mucin induction by dsRNA was blocked by the P2Y
receptor antagonist RB2 as well as the ATP conductance in-
hibitors gadolinium and glibenclamide (Fig. 5). Importantly,
these drugs did not block mucin induction by LPS, illustrating
the diversity of mechanisms by which mucin can be induced
by pathogens at the cell surface.
The notion that autocrine/paracrine nucleotide signaling
mediates host defense responses is novel in the context of
epithelial cells, but had been described earlier for mast cells,
macrophages, eosinophils and lymphocytes [29^32]. Paracrine
signaling, in particular, may be of great bene¢t in propagating
defensive responses from one or a few pathogen-exposed cells
to neighboring cells in a mucosal epithelium. Although the
means by which ATP is released from mucosal cells is unclear,
it has been suggested that ATP extrusion is mediated by the
ABC transporter family, at least one member of which, the
cystic ¢brosis transmembrane conductance regulator, is
present in mucosal tissues [33,34].
In summary, our data provide details of a novel signaling
pathway responsible for the induction of mucin in epithelial
cells by viral dsRNA. This pathway may underlie mucus over-
production during respiratory viral infections, in which case
P2Y nucleotide receptors, PLC, PKC and p38 could be drug
targets for relief of the common cold. Moreover, because the
activation of p38 and JNK is dependent on nucleotide recep-
tor signaling, P2Y antagonists might play a relatively broad
role in controlling viral pathogenesis.
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